Answers are grounded in this paper and cite their sources.
Antimicrobial resistance has emerged as one of the most critical global health threats, with forecasts projecting 10 million annual deaths by 2050 if no effective interventions are implemented. The declining pipeline of novel antibiotics has necessitated the exploration of alternative therapeutic strategies. Bacteriophage endolysins have emerged as promising candidates to address this crisis. However, the clinical and commercial translation of endolysins is contingent upon the availability of robust, scalable, and cost-effective production platforms. This review provides a critical overview of the endolysin production landscape, from discovery and bioinformatic identification through cloning, expression, purification, and industrial-scale manufacturing. We critically evaluate the diversity of expression systems employed in recent research, including Escherichia coli , lactic acid bacteria (LAB), yeasts ( Pichia pastoris , Hansenula polymorpha , Saccharomyces cerevisiae ), plant-based platforms, and microalgal chloroplasts, discussing key considerations guiding host selection. Particular attention is given to plant-produced endolysins, including a defined endolysin preparation for which the FDA issued a “no questions” response to a GRAS notice for specified food-safety applications, and to the emerging Corynebacterium glutamicum secretion system as a potential alternative for endotoxin-free production. We also examine evidence-graded, hypothetical frameworks for scaling endolysin production to industrial volumes, addressing bioprocess parameters, purification strategies, and regulatory pathways. By synthesizing current knowledge and identifying critical gaps, particularly the scarcity of systematic comparative studies, underdeveloped downstream processing strategies, and limited integration of techno-economic and regulatory planning, this review aims to guide researchers and industry stakeholders in advancing endolysin-based antimicrobials from laboratory promise toward clinical and commercial reality. With continued advances in production technology and regulatory alignment, endolysins are well-positioned to contribute significantly to combating antimicrobial-resistant infections.
No takes yet. Share an insight, caveat, or question.
Rahimian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: